Suchergebnisse - "Jimenez-Zepeda, Victor H"

PubPharm (117)

1

Daratumumab for the treatment of relapsed/refractory AL amyloidosis : experience from the amyloidosis Program of Calgary (APC)

enthalten in: Leukemia & lymphoma | 2024

von Levin, D. | Lewis, E. | McCulloch, S. | +6

2

Long‐term survivorship care after CAR‐T cell therapy

enthalten in: European Journal of Haematology | 2024

von Puckrin, R. | Jamani, K. | Jimenez‐Zepeda, V.

3

Long-term survivorship care after CAR-T cell therapy

enthalten in: European journal of haematology | 2024

von Puckrin, R. | Jamani, K. | Jimenez-Zepeda, V.

4

Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens : Experience From the Amyloidosis Program of Calgary

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lewis, E. | McCulloch, S. | Mahe, E. | +5

5

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma : a report from the Canadian Myeloma Research Group database

enthalten in: Blood cancer journal | 2023

von Côté, J. | LeBlanc, R. | Mian, H. | +18

6

Correction : Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

enthalten in: Blood cancer journal | 2023

von McCurdy, A. | Mian, H. | LeBlanc, R. | +17

ErratumFor: Blood Cancer J. 2023 Jul 20;13(1):111. - PMID 37474492

7

Redefining attrition in multiple myeloma (MM) : a Canadian Myeloma Research Group (CMRG) analysis

enthalten in: Blood cancer journal | 2023

von McCurdy, A. | Mian, H. | LeBlanc, R. | +17

ErratumIn: Blood Cancer J. 2023 Aug 28;13(1):129. - PMID 37635183

8

Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR) : Analysis Using the iStopMM Criteria

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lewis, E. | Lee, H. | Fine, N. | +6

9

Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Nie, C. | Lee, H. | Tay, J. | +5

10

Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma : Results from the Canadian Myeloma Research Group Database

enthalten in: Cancer medicine | 2023

von Mian, H. | LeBlanc, R. | Louzada, M. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]